Investors

EXECUTIVE SUMMARY

THE PROBLEM

“The ability to generate a very good quality technical sequence of the human genome exists. But there is a massive gap between having the data in front of us and knowing what it all means”.

Quote from December 2020 interview with Dr. Eric Green, head of the National Human Genome Research Institute (Leading US genomic research organization.)

The unsolved interpretation of the Human Genome and the untapped mining of its true potential is one of the most important scientific challenges of our time. Once solved, a key application of this knowledge would be in the area of drug discovery and development which has involves significant funding and has high failure rates.

OUR SOLUTION

GNQ’s exclusive license from its’ parent company, My Next Health (MNH), for proprietary genomic insights, coupled with its innovative approach that integrates genomics, AI, and quantum computing, positions the company at the forefront of advancements in drug discovery and development. This holistic approach has the potential to reshape the field and contribute to more targeted and effective treatments for a wide range of diseases.

Rich Dataset

The dataset derived from over 15,000 case studies is a substantial and diverse source of information. Including a wide range of genetic, environmental, lifestyle, and health-related data, making it a valuable resource for understanding the underlying causes of diseases and cellular behavior.

Factors Influencing Cellular Behavior

GNQ's approach takes a comprehensive approach essential for gaining insights into complex diseases including factors influencing cellular behaviours such as genetic pathways, environmental factors, lifestyle choices, diet, exercise, and more.

Genomics, AI, and Quantum Computing

The integration of genomics, AI, and quantum computing represents a cutting-edge approach to drug discovery and development. Genomics provides insights into the genetic basis of diseases, AI can analyze and interpret vast datasets, and quantum computing can tackle complex simulations and calculations that were previously challenging.

Novel Approach

GNQ's platform introduces a novel approach to drug discovery. By leveraging deep genomic understanding and advanced technologies, it has the potential to identify novel drug targets, optimize drug molecules, and predict treatment responses with greater precision.

Accelerated Research

The combination of proprietary genomic insights and advanced technologies can significantly accelerate the research and development process. This can lead to faster discoveries and potentially more effective treatments for a wide range of diseases.

Ethical and Privacy Considerations

Given the sensitive nature of genomic and health data, it's crucial for GNQ to maintain rigorous ethical standards and data privacy measures to protect individuals' information.

Collaboration and Validation

Collaborations with research institutions, clinical experts, and regulatory bodies are essential for validating the findings and ensuring that they meet regulatory standards for drug development.

Previous slide

Next slide

THE OPPORTUNITY

Having a first-mover advantage in the rapidly growing drug discovery and development market is a significant asset, and it opens up several strategic opportunities for GNQ. Here are some key considerations:

Platform Licensing Opportunities

Being a pioneer in this space allows GNQ to explore platform licensing opportunities. Licensing its proprietary technologies, insights, or platforms to other pharmaceutical companies, research institutions, or startups will create new revenue streams and establish GNQ as a leader in the industry.

Collaborations with Strategic Partners

Partnering with key players in the life sciences and healthcare industries can provide access to resources, expertise, and distribution channels. Collaborations can enhance research capabilities, accelerate product development, and broaden the reach of GNQ's innovations.

Research and Development Acceleration

GNQ's first-mover advantage positions it to lead in innovative drug discovery methods. This can result in faster and more efficient research and development processes, leading to a competitive edge in bringing new therapies to market.

Market Leadership

By establishing itself as a first mover, GNQ will build a strong reputation and credibility in the industry. This leadership position attracts talent, investors, and potential partners interested in being part of a ground-breaking endeavor.

Diversification of Offerings

Beyond drug discovery, GNQ can diversify its offerings by exploring applications in diagnostics, personalized medicine, and healthcare analytics. This diversification can provide resilience and opportunities for growth.

Long-Term Vision

GNQ has a clear long-term vision for its role in the drug discovery and healthcare ecosystem. This includes planning for scalability, sustainability, and adaptation to evolving technologies and market dynamics.

Customer-Centric Approach

GNQ prioritizes a customer-centric approach by tailoring solutions to meet the specific needs of clients in the life sciences and healthcare industries. Understanding their pain points and offering solutions that address them is key to success.

Previous slide

Next slide

CORPORATE PRESENTATION

INTRODUCING GNQ INSILICO

Find out more about the company, our platform and technologies, and the people behind the idea in our Corporate Presentation.

INVESTOR RELATIONS

If you would like contact our Investor Relations team, use the form below.

INVESTORS